Popular Trials
SGLT2 Inhibitor
Zibotentan + Dapagliflozin for Liver Cirrhosis
This trial is testing a combination of two drugs, zibotentan and dapagliflozin, and also dapagliflozin alone. It targets people with liver disease (cirrhosis) that causes high blood pressure in the liver's veins. The treatment aims to lower this high blood pressure and improve liver health. Dapagliflozin is a medication that has been shown to reduce cardiovascular death and heart failure.
Cancer Preventive Agent
Green Tea Extract for Liver Cirrhosis
This trial studies the effects of a green tea extract on people with cirrhosis. The goal is to find the best dose and see if it can lower a molecule linked to liver cancer. By reducing this molecule, the treatment may help prevent liver cancer in these patients. Green tea extract has been shown to protect against various forms of liver damage, including those induced by alcohol, acetaminophen, and carbon tetrachloride.
Popular Filters
Trials for Non-alcoholic Fatty Liver Disease Patients
Noninvasive SHAPE for Portal Hypertension
This trial will study if the SHAPE algorithm can accurately estimate portal pressures in patients with various degrees of liver disease, if it can predict the development of ascites and other liver-related events, and if it can be used to monitor treatment response in patients with portal hypertension.
Trials for Liver Cancer Patients
HMG-CoA Reductase Inhibitor
Simvastatin for Preventing Liver Cancer in Patients With Cirrhosis
This trial studies if simvastatin can prevent liver cancer in patients with liver cirrhosis. Simvastatin, usually used to lower cholesterol, might block enzymes that cancer cells need to grow. The trial targets patients with liver disease. Simvastatin has been shown to reduce the risk of liver cancer and improve outcomes in these patients.
Contrast Agent
AMRI vs. Ultrasound for Liver Cancer Surveillance
This trial compares the use of gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for the screening and surveillance of subjects with liver cirrhosis who are at risk for developing hepatocellular carcinoma (HCC).
Namodenoson for Liver Cancer
This trial tests an oral medication on patients with advanced liver cancer who have not responded to previous treatments. The goal is to see if this medication can slow down or stop the growth of cancer cells in the liver. The medication is being developed to treat liver cancer, where longer survival was observed in patients with advanced liver disease.
Phase 3 Trials
Statin
Simvastatin for Liver Cirrhosis
This trial tests if simvastatin can prevent serious liver problems in U.S. Veterans with early-stage liver damage. Simvastatin not only lowers cholesterol but also helps protect the liver from further damage and reduces the risk of severe liver issues. Statins, including simvastatin, have been increasingly recognized for their potential benefits in treating chronic liver diseases, including cirrhosis, by reducing portal pressure and protecting against liver damage.
Namodenoson for Liver Cancer
This trial tests an oral medication on patients with advanced liver cancer who have not responded to previous treatments. The goal is to see if this medication can slow down or stop the growth of cancer cells in the liver. The medication is being developed to treat liver cancer, where longer survival was observed in patients with advanced liver disease.
Noninvasive SHAPE for Portal Hypertension
This trial will study if the SHAPE algorithm can accurately estimate portal pressures in patients with various degrees of liver disease, if it can predict the development of ascites and other liver-related events, and if it can be used to monitor treatment response in patients with portal hypertension.
Thyroid Hormone Receptor Agonist
Resmetirom for NASH Cirrhosis
This trial tests a daily pill called resmetirom for people with a stable form of liver disease not caused by alcohol. The goal is to see if the drug can improve liver function and reduce liver fat, thereby preventing serious complications. Resmetirom has been tested in previous studies for the treatment of liver disease.
Trials With No Placebo
Endothelin Receptor Antagonist
Zibotentan for Non-invasive Indices to Predict Hepatic Fibrosis in BA Patients.
"This trial aims to study how the body processes Zibotentan in healthy participants from different ethnic backgrounds, including non-Asian and Japanese individuals."
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Somatostatin Analog
Octreotide Infusion Duration for Esophageal Varices
This trial compares the safety and effectiveness of shorter versus longer octreotide infusion in cirrhotic patients with bleeding esophageal varices. Octreotide helps lower blood pressure in liver vessels, reducing bleeding risks. The study aims to see if a shorter treatment duration is just as safe and effective, potentially lowering hospital costs. Octreotide is a synthetic long-acting somatostatin analogue used to control acute esophageal variceal bleeding by reducing variceal blood flow and pressure.
View More Related Trials
Frequently Asked Questions
Introduction to liver cirrhosis
What are the top hospitals conducting liver cirrhosis research?
When it comes to advancing the treatment and understanding of liver cirrhosis, several top hospitals across the United States are leading the way. In Boston, Massachusetts General Hospital stands out with six active clinical trials dedicated to this condition. With a total of 15 liver cirrhosis trials conducted since their first recorded trial in 2000, this renowned institution has been at the forefront of research and innovation in liver health.
Heading west to Rochester, Minnesota, we find another prestigious hospital making significant contributions. The Mayo Clinic currently has five ongoing liver cirrhosis trials and an impressive history of 23 completed studies dating back to their initial trial in 1997. Known for its cutting-edge medical expertise, Mayo Clinic is committed to improving outcomes for patients with liver cirrhosis.
In Pasadena, California Liver Research Institute is making strides in liver health as well. With four active clinical trials focused on liver cirrhosis and a growing portfolio of 11 all-time studies since their first recorded trial in 2015, this institute emphasizes cutting-edge research and personalized care for patients affected by this condition.
Moving further down south to Richmond, Virginia, Hunter Holmes McGuire VA Medical Center is actively involved in addressing liver cirrhosis through four ongoing clinical trials. Since recording their first trial for this condition in 2011, they have built a robust history with a total of 19 completed studies aimed at enhancing diagnosis and treatment options for individuals living with liver cirrhosis.
Lastly but certainly not least important is University of California San Francisco located right within San Francisco itself; here researchers are conducting three rigorous clinical tests towards battling against cases associated with livecirhossis while also contributing significantly towards progress through seven previously held investigations starting from recordationof there venture into such experiments during years as recent as2013.Their location allows them access countless resources support which only furthers advancements made by staff & physicians alike
These distinguished hospitals illustrate how collaborative research efforts and innovative clinical trials are paving the way for improved outcomes in liver cirrhosis management. With each study and trial, these institutions bring us closer to more effective treatments, enhanced quality of life for patients, and ultimately a future where liver cirrhosis can be prevented or treated with greater success.
Which are the best cities for liver cirrhosis clinical trials?
When it comes to liver cirrhosis clinical trials, several cities emerge as prominent hubs for cutting-edge research. Los Angeles, California leads the way with 18 ongoing trials investigating treatments like PF-06865571, Active, and CSG452. Following closely behind is Richmond, Virginia with 17 active studies focusing on belapectin, OCE-205, and Health IT +/- Scheduled Follow Up. Miami, Florida also showcases a strong presence in the field with 16 trials exploring IVA337, PF-06865571, and Cohort C: Rencofilstat 225 mg. Lastly, New york City boasts 14 active trials studying belapectin and PF-06865571 among others. These cities offer individuals affected by liver cirrhosis access to cutting-edge clinical trials that advance our understanding of this complex condition and pave the way for improved treatments in the future.
Which are the top treatments for liver cirrhosis being explored in clinical trials?
The search for effective treatments for liver cirrhosis is ongoing, with several promising options currently being explored in clinical trials. Leading the charge is the Jumpstart Guide, a novel approach that has caught researchers' attention. It is currently involved in one active trial focused on liver cirrhosis and marks its first listing in 2023. Another contender making waves in the field is Hepatology Home Hospital, also engaged in one active liver cirrhosis trial since 2023. Lastly, LPCN 1148 shows potential as a treatment option through its involvement in one active trial and first listing in 2021. These innovative therapies offer hope for patients battling this challenging condition and may pave the way to improved outcomes.
What are the most recent clinical trials for liver cirrhosis?
Exciting advancements in the treatment of liver cirrhosis are emerging through recent clinical trials. One notable trial, named Active, is currently in Phase 2 and offers potential breakthroughs for individuals with this condition. Another study, Arm 1, has progressed to Phase 3 and holds promise as a viable option for those suffering from liver cirrhosis. Additionally, Semaglutide exhibits encouraging results in its Phase 2 trial for this disease. Furthermore, a Phase 3 trial focusing on the combination of lactulose treatment alongside enhanced usual care demonstrates promising outcomes for patients with liver cirrhosis. Lastly, Bemnifosbuvir and Ruzasvir show potential benefits based on their ongoing Phase 2 evaluation. These trials collectively offer hope for improved treatments and better quality of life among individuals battling liver cirrhosis.
(Corrected response)
What liver cirrhosis clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of liver cirrhosis research, offering hope for patients grappling with this complex condition. In November 2021 alone, two important trials were completed: one sponsored by Stanford University focusing on Empagliflozin 10 MG and another led by the University of Michigan investigating Lactulose. Additionally, Georgetown University's Proglumide trial concluded in March 2021. These breakthroughs build upon earlier advancements from a range of sponsors including Beth Israel Deaconess Medical Center, NGM Biopharmaceuticals Inc., Novartis Pharmaceuticals, Hunter Holmes Mcguire Veteran Affairs Medical Center, Bristol-Myers Squibb, and Intercept Pharmaceuticals between 2017 to 2020. This collective effort signifies the commitment of researchers towards unraveling new therapeutic approaches for liver cirrhosis patients.